| 1 | Treatment failure (i.e. virological, immunological, and/or clinical failure | 
					| 1.1 | Virological failure | 
					| 1.2 | Partial virological failure | 
					| 1.3 | Immunological failure - CD4 drop | 
					| 1.4 | Clinical progression | 
					| 1.5 | Resistance (based on test result) | 
					| 10 | Hyperlactataemie/lactic acidosis | 
					| 11 | Bone toxicity | 
					| 15 | Social contra-indication | 
					| 16 | Contra-indication unspecified | 
					| 16.8 | Contra-indication expired | 
					| 16.9 | Contra-indication – other | 
					| 17 | MTCT regimen completed | 
					| 2 | Abnormal fat redistribution | 
					| 3 | Concern of cardiovascular disease | 
					| 3.1 | Dyslipidaemia | 
					| 3.2 | Cardiovascular disease | 
					| 4 | Hypersensitivity reaction (skin eruption etc.) | 
					| 5 | Toxicity, predominantly from abdomen/G-I tract | 
					| 5.1 | Toxicity - GI tract | 
					| 5.2 | Toxicity - Liver | 
					| 5.3 | Toxicity - Pancreas | 
					| 6 | Toxicity, predominantly from nervous system | 
					| 6.1 | Toxicity - peripheral neuropathy | 
					| 6.2 | Toxicity - neuropsychiatric | 
					| 6.3 | Toxicity - headache | 
					| 7 | Toxicity, predominantly from kidneys | 
					| 70 | Pregnancy - toxicity concerns (during pregnancy) | 
					| 75 | Pregnancy - switch to a more appropriate regimen for PMTCT | 
					| 8 | Toxicity, predominantly from endocrine system | 
					| 8.1 | Diabetes | 
					| 88 | Death | 
					| 9 | Haematological toxicity (anemia etc.) | 
					| 90 | Side effects - any of the above but unspecified | 
					| 90.1 | Comorbidity | 
					| 91 | Toxicity, not mentioned above | 
					| 91.1 | Toxicity, unspecified | 
					| 92 | Availability of more effective treatment (not specifically failure or side effect related) | 
					| 92.1 | Simplified treatment available | 
					| 92.2 | Treatment too complex | 
					| 92.3 | Drug interaction | 
					| 92.31 | Drug interaction - commencing TB/BCG treatment | 
					| 92.32 | Drug interaction - ended TB/BCG treatment | 
					| 92.33 | Change in eligibility criteria (e.g. child old enough for tablets; refrigerator no longer available) | 
					| 92.4 | Protocol change | 
					| 92.5 | Regular treatment termination (used in tblMED e.g. for DAA's against HCV, antibiotics) | 
					| 92.6 | End of empiric treatment | 
					| 92.9 | Change in treatment not due to side-effects, failure, poor adherence or contra-indication | 
					| 93 | Structured Treatment Interruption (STI) | 
					| 93.1 | Structured Treatment Interruption (STI) - at high CD4 | 
					| 94 | Patient's wish/decision, not specified above | 
					| 94.1 | Non-compliance | 
					| 94.2 | Defaulter | 
					| 95 | Physician's decision, not specified above | 
					| 96 | Pregnancy (see also more specific codes 70 and 75 | 
					| 96.1 | Pregnancy intended | 
					| 96.2 | Pregnancy ended | 
					| 97 | Study treatment | 
					| 97.1 | Study treatment commenced | 
					| 97.2 | Study treatment completed | 
					| 97.6 | Drug not available | 
					| 98 | Other causes, not specified above | 
					| 99 | Unknown |